

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Osimertinib with pemetrexed and platinum-based
chemotherapy for untreated EGFR mutation-positive
advanced non-small-cell lung cancer [ID6328]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential equality issues raised during scoping.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee noted that people with an Asian family background were more likely to have EGFR-positive advanced NSCLC. Because its recommendation does not restrict access to treatment for some people over others, the committee agreed this was not an equalities issue.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes – paragraph 3.17

Approved by Associate Director (name): Ian Watson

Date: 22 October 2024

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Yes, an additional patient submission received during consultation noted that: 'EGFR affects certain groups more than others (for example, it is more prevalent in women, and in Asian populations). Ensuring access to treatment and information about the treatment is relevant and understandable to these groups is essential.'

The committee agreed this was not an equalities issue. Issues regarding access to treatment and information about treatment relate to implementation and cannot be addressed within a technology appraisal recommendation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations are not expected to have a differential impact on access to the technology for any specific groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations are not expected to have an adverse impact on people with disabilities.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
N/A

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes – paragraph 3.21

Approved by Associate Director (name): Ian Watson

Date: 25 March 2025